171 related articles for article (PubMed ID: 32238882)
1. Temporal activation of WNT/β-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth.
Uka R; Britschgi C; Krättli A; Matter C; Mihic D; Okoniewski MJ; Gualandi M; Stupp R; Cinelli P; Dummer R; Levesque MP; Shakhova O
Oncogene; 2020 May; 39(20):4132-4154. PubMed ID: 32238882
[TBL] [Abstract][Full Text] [Related]
2. SOX10, a novel HMG-box-containing tumor suppressor, inhibits growth and metastasis of digestive cancers by suppressing the Wnt/β-catenin pathway.
Tong X; Li L; Li X; Heng L; Zhong L; Su X; Rong R; Hu S; Liu W; Jia B; Liu X; Kou G; Han J; Guo S; Hu Y; Li C; Tao Q; Guo Y
Oncotarget; 2014 Nov; 5(21):10571-83. PubMed ID: 25301735
[TBL] [Abstract][Full Text] [Related]
3. SOX10 is a novel oncogene in hepatocellular carcinoma through Wnt/β-catenin/TCF4 cascade.
Zhou D; Bai F; Zhang X; Hu M; Zhao G; Zhao Z; Liu R
Tumour Biol; 2014 Oct; 35(10):9935-40. PubMed ID: 25001176
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor effects of differentiation-inducing factor-1 in malignant melanoma: GSK-3-mediated inhibition of cell proliferation and GSK-3-independent suppression of cell migration and invasion.
Arioka M; Takahashi-Yanaga F; Kubo M; Igawa K; Tomooka K; Sasaguri T
Biochem Pharmacol; 2017 Aug; 138():31-48. PubMed ID: 28501501
[TBL] [Abstract][Full Text] [Related]
5. SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects.
Rosenbaum SR; Tiago M; Caksa S; Capparelli C; Purwin TJ; Kumar G; Glasheen M; Pomante D; Kotas D; Chervoneva I; Aplin AE
Cell Rep; 2021 Dec; 37(10):110085. PubMed ID: 34879275
[TBL] [Abstract][Full Text] [Related]
6. MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells.
Fufa TD; Baxter LL; Wedel JC; Gildea DE; ; Loftus SK; Pavan WJ
Epigenetics Chromatin; 2019 Aug; 12(1):50. PubMed ID: 31399133
[TBL] [Abstract][Full Text] [Related]
7. Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma.
Shakhova O; Cheng P; Mishra PJ; Zingg D; Schaefer SM; Debbache J; Häusel J; Matter C; Guo T; Davis S; Meltzer P; Mihic-Probst D; Moch H; Wegner M; Merlino G; Levesque MP; Dummer R; Santoro R; Cinelli P; Sommer L
PLoS Genet; 2015 Jan; 11(1):e1004877. PubMed ID: 25629959
[TBL] [Abstract][Full Text] [Related]
8. SOX9 is a dose-dependent metastatic fate determinant in melanoma.
Yang X; Liang R; Liu C; Liu JA; Cheung MPL; Liu X; Man OY; Guan XY; Lung HL; Cheung M
J Exp Clin Cancer Res; 2019 Jan; 38(1):17. PubMed ID: 30642390
[TBL] [Abstract][Full Text] [Related]
9. Sox10 controls migration of B16F10 melanoma cells through multiple regulatory target genes.
Seong I; Min HJ; Lee JH; Yeo CY; Kang DM; Oh ES; Hwang ES; Kim J
PLoS One; 2012; 7(2):e31477. PubMed ID: 22363655
[TBL] [Abstract][Full Text] [Related]
10. Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3.
Atkinson JM; Rank KB; Zeng Y; Capen A; Yadav V; Manro JR; Engler TA; Chedid M
PLoS One; 2015; 10(4):e0125028. PubMed ID: 25915038
[TBL] [Abstract][Full Text] [Related]
11. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
[TBL] [Abstract][Full Text] [Related]
12. Identification and functional analysis of SOX10 phosphorylation sites in melanoma.
Cronin JC; Loftus SK; Baxter LL; Swatkoski S; Gucek M; Pavan WJ
PLoS One; 2018; 13(1):e0190834. PubMed ID: 29315345
[TBL] [Abstract][Full Text] [Related]
13. The miR-31-SOX10 axis regulates tumor growth and chemotherapy resistance of melanoma via PI3K/AKT pathway.
Zheng Y; Sun Y; Liu Y; Zhang X; Li F; Li L; Wang J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2451-2458. PubMed ID: 29969627
[TBL] [Abstract][Full Text] [Related]
14. Neural cell adhesion molecule potentiates the growth of murine melanoma via β-catenin signaling by association with fibroblast growth factor receptor and glycogen synthase kinase-3β.
Liu R; Shi Y; Yang HJ; Wang L; Zhang S; Xia YY; Wong JL; Feng ZW
J Biol Chem; 2011 Jul; 286(29):26127-37. PubMed ID: 21628472
[TBL] [Abstract][Full Text] [Related]
15. UBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling.
Dikshit A; Jin YJ; Degan S; Hwang J; Foster MW; Li CY; Zhang JY
Cancer Res; 2018 Nov; 78(22):6462-6472. PubMed ID: 30224375
[TBL] [Abstract][Full Text] [Related]
16. [Nuclear beta-catenin localization is not sufficient for canonical Wnt signaling activation in human meianoma cell lines].
Kulikova KV; Posviatenko AV; Gnuchev NV; Georgiev GP; Kibardin AV; Larin SS
Mol Biol (Mosk); 2011; 45(5):884-91. PubMed ID: 22393786
[TBL] [Abstract][Full Text] [Related]
17. Suppression of casein kinase 1alpha in melanoma cells induces a switch in beta-catenin signaling to promote metastasis.
Sinnberg T; Menzel M; Kaesler S; Biedermann T; Sauer B; Nahnsen S; Schwarz M; Garbe C; Schittek B
Cancer Res; 2010 Sep; 70(17):6999-7009. PubMed ID: 20699366
[TBL] [Abstract][Full Text] [Related]
18. Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma.
Shakhova O; Zingg D; Schaefer SM; Hari L; Civenni G; Blunschi J; Claudinot S; Okoniewski M; Beermann F; Mihic-Probst D; Moch H; Wegner M; Dummer R; Barrandon Y; Cinelli P; Sommer L
Nat Cell Biol; 2012 Aug; 14(8):882-90. PubMed ID: 22772081
[TBL] [Abstract][Full Text] [Related]
19. Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor.
Widlund HR; Horstmann MA; Price ER; Cui J; Lessnick SL; Wu M; He X; Fisher DE
J Cell Biol; 2002 Sep; 158(6):1079-87. PubMed ID: 12235125
[TBL] [Abstract][Full Text] [Related]
20. SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis.
Yokoyama S; Takahashi A; Kikuchi R; Nishibu S; Lo JA; Hejna M; Moon WM; Kato S; Zhou Y; Hodi FS; Song JS; Sakurai H; Fisher DE; Hayakawa Y
Cancer Res; 2021 Dec; 81(24):6131-6141. PubMed ID: 34728538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]